Use of DOACs after 5 Days of LMWH in VTE Management: Real‑World Adherence to Trial Protocols in Internal Medicine Unit

Abstract

Background and Aims: Direct oral anticoagulants (DOACs) are a cornerstone in the treatment of venous thromboembolism (VTE). Trials specify distinct initiation protocols: edoxaban and dabigatran require ≥5 days of low-molecular-weight heparin (LMWH), while apixaban and rivaroxaban allow direct initiation with loading. This study evaluates real-world adherence to these regimens in a Internal Medicine Unit.